Pharmacokinetic evaluation of piperacillin-tazobactam

被引:69
|
作者
Hayashi, Yoshiro [2 ]
Roberts, Jason A. [1 ,3 ,4 ]
Paterson, David L. [2 ,5 ]
Lipman, Jeffrey [1 ,3 ]
机构
[1] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld, Australia
[2] Univ Queensland, Clin Res Ctr, Brisbane, Qld, Australia
[3] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Qld, Australia
[4] Royal Brisbane & Womens Hosp, Dept Pharm, Brisbane, Qld, Australia
[5] Royal Brisbane & Womens Hosp, Dept Infect Dis, Brisbane, Qld, Australia
基金
英国医学研究理事会;
关键词
beta-lactamases; pharmacodynamics; pharmacokinetics; piperacillin-tazobactam; Pseudomonas aeruginosa; INFECTIOUS-DISEASES-SOCIETY; CRITICALLY-ILL PATIENTS; IN-VITRO ACTIVITY; CONTINUOUS VENOVENOUS HEMOFILTRATION; SINGLE-DOSE PHARMACOKINETICS; BETA-LACTAM ANTIBIOTICS; INTENSIVE-CARE-UNIT; DOUBLE-BLIND; CONTINUOUS-INFUSION; ANTIMICROBIAL SUSCEPTIBILITY;
D O I
10.1517/17425255.2010.506187
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Importance of the field: Piperacillin-tazobactam is a frequently prescribed intravenous antibiotic for moderate to severe infections used in hospital settings because of its broad activity against many pathogenic bacteria including Pseudomonas aeruginosa. However, its pharmacokinetics (PK) can be significantly altered in a variety of states. Areas covered in this review: This article provides a comprehensive and critical review of the PK of piperacillin-tazobactam in different patient populations. The pharmacodynamics (PD) of piperacillin-tazobactam is also discussed. What the reader will gain: The importance of appropriate antibiotic dosing in the context of the global tendency for reduced susceptibility of bacteria, including P. aeruginosa is emphasized. The interrelationship between PK and PD is discussed to provide an understanding of methods for procuring dosing regimens that increase the likelihood of clinical success for individual patients. Alternative dosing regimens, which may include administration by extended or continuous infusion of piperacillin-tazobactam as a mechanism to increase the likelihood of pharmacodynamic target attainment, are described. Take home message: Where piperacillin-tazobactam is required for treatment, applying knowledge of PK and PD characteristics can facilitate optimal outcomes.
引用
收藏
页码:1017 / 1031
页数:15
相关论文
共 50 条
  • [21] Fixed Drug Eruption Caused by Piperacillin-Tazobactam
    Santosa, A.
    Teo, B. W.
    Shek, L. P-C
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2013, 23 (02) : 132 - 133
  • [22] EFFECT OF PIPERACILLIN-TAZOBACTAM THERAPY ON INTESTINAL MICROFLORA
    NORD, CE
    BRISMAR, B
    KASHOLMTENGVE, B
    TUNEVALL, G
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1992, 24 (02) : 209 - 213
  • [23] A CASE REPORT ON PIPERACILLIN-TAZOBACTAM INDUCED TRANSAMINITIS
    Joseph, Aida Mary
    Mathew, Elza
    Shaji, Jeethu K.
    Prakash, Aleena
    Menaka, K.
    Sivakumar, T.
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 5 (10): : 9761 - 9763
  • [24] EVALUATION OF PIPERACILLIN-TAZOBACTAM CONTINUOUS-INFUSION CLEARANCE IN BURN PATIENTS
    Bertolaccini, Corinne
    Prazak, Ann Marie
    CRITICAL CARE MEDICINE, 2020, 48
  • [25] Piperacillin-tazobactam as alternative to carbapenems for ICU patients
    Pilmis, Benoit
    Jullien, Vincent
    Tabah, Alexis
    Zahar, Jean-Ralph
    Brun-Buisson, Christian
    ANNALS OF INTENSIVE CARE, 2017, 7
  • [26] Vancomycin/Piperacillin-tazobactam Nephrotoxicity in the Critically Ill
    Kollef, Marin H.
    Juang, Paul
    Micek, Scott T.
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (07) : 1520 - 1521
  • [27] Rationale and evidence for extended infusion of piperacillin-tazobactam
    Kaufman, Scott E.
    Donnell, Robert W.
    Hickey, W. Scott
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (16) : 1521 - 1526
  • [28] Appropriate prescribing of piperacillin-tazobactam in a teaching hospital
    Fanny, V.
    Sneyers, B.
    Yombi, J. -C.
    Jonckeere, S.
    Belkhir, L.
    Briquet, C.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 990 - 990
  • [29] PIPERACILLIN-TAZOBACTAM PHARMACOKINETICS IN PATIENTS WITH INTRAABDOMINAL INFECTIONS
    JHEE, SS
    KERN, JW
    BURM, JP
    YELLIN, AE
    GILL, MA
    PHARMACOTHERAPY, 1995, 15 (04): : 472 - 478
  • [30] Sensitization phenotypes in immediate reactions to piperacillin-tazobactam
    Gallardo, Alicia
    Moreno, Esther M.
    Laffond, Elena
    Munoz-Bellido, Francisco J.
    Teresa Gracia-Bara, M.
    Macias, Eva M.
    Valle Campanon, M.
    de Arriba, Sonia
    Martin, Cristina
    Sobrino, Miriam
    Davila, Ignacio
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2020, 8 (09): : 3175 - 3177